Highlights
• AusCann’s Chilean joint venture DayaCann has signed a non-binding MoU with Canadian listed medical cannabis company Khiron Life Sciences Corp. (TSXV:KHRN)
• AusCann and Fundacio´n Daya formed DayaCann in late 2016 and have completed two harvests at DayaCann’s 30-hectare facility yielding a total of over 1000kg of dried cannabis
• Khiron has its core medicinal cannabis operations in Colombia, where it is fully licensed for the cultivation, production, distribution and export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis
• Under the MoU, DayaCann, Fundacio´n Daya and Khiron will collaborate on the development of social, pedagogical, scientific, commercial and political activities to support cannabinoid medicines as a medical option.
Monday, 1 October 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to announce that its Chilean joint venture DayaCann has signed a non-binding Memorandum of Understanding (MoU) with Canadian listed medical cannabis company Khiron Life Sciences Corp. (TSXV:KHRN) (‘Khiron’).
For further information please download PDF attached:
Download this document
